250 related articles for article (PubMed ID: 29227547)
1. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis.
Liu GF; Wang ZQ; Liu L; Zhang BT; Miao YY; Yu SN
J Cell Biochem; 2018 Jun; 119(6):4469-4481. PubMed ID: 29227547
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
4. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
Wang YK; Qin SQ; Ma T; Song W; Jiang RQ; Guo JB; Li K; Zhang YM
Medicine (Baltimore); 2017 May; 96(21):e6970. PubMed ID: 28538396
[TBL] [Abstract][Full Text] [Related]
5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
6. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Alendronate upon Vertebral Bone Mineral Density and Fracture Rates in East Asians Versus Non-East Asians with Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis.
Wang Y; Jia G; Song J; Kong X; Zhang W; Meng C
Horm Metab Res; 2018 Oct; 50(10):738-746. PubMed ID: 30312984
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
9. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
[TBL] [Abstract][Full Text] [Related]
12. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
14. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Wang WY; Chen LH; Ma WJ; You RX
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(17):8253-8268. PubMed ID: 37750653
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
16. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
17. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials.
Xu Z
Am J Ther; 2017; 24(2):e130-e138. PubMed ID: 27058577
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Shen J; Ke Z; Dong S; Lv M; Yuan Y; Song L; Wu K; Xu K; Hu Y
Med Sci Monit; 2022 Apr; 28():e935491. PubMed ID: 35430576
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Huang W; Nagao M; Yonemoto N; Guo S; Tanigawa T; Nishizaki Y
Pharmacoepidemiol Drug Saf; 2023 Jun; 32(6):671-684. PubMed ID: 36703260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
